Characterizing preferences for health outcomes in economic evaluations

Affiliations

Review

Anna N Tosteson. J Rheumatol Suppl. 2003 Dec.

. 2003 Dec:68:15-8.

¹ Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA. Anna.Tosteson@Dartmouth.edu

No abstract available

Similar articles

Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
Oldridge N, Furlong W, Perkins A, Feeny D, Torrance GW. Oldridge N, et al. Eur J Cardiovasc Prev Rehabil. 2008 Oct;15(5):608-15. doi: 10.1097/HJR.0b013e328304fec1. Eur J Cardiovasc Prev Rehabil. 2008. PMID: 18800005 Clinical Trial.
Cost effectiveness analysis--assessing the assumptions behind the assumptions.
Johnson K. Johnson K. J Rheumatol. 2000 Jun;27(6):1565-7. J Rheumatol. 2000. PMID: 10852296 No abstract available.
The use of quality-adjusted life-years in cost-effectiveness studies.
Sculpher M. Sculpher M. Allergy. 2006 May;61(5):527-30. doi: 10.1111/j.1398-9995.2006.01053.x. Allergy. 2006. PMID: 16629779 No abstract available.
Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
McNaughton-Collins M, Walker-Corkery E, Barry MJ. McNaughton-Collins M, et al. J Natl Cancer Inst Monogr. 2004;(33):78-101. doi: 10.1093/jncimonographs/lgh016. J Natl Cancer Inst Monogr. 2004. PMID: 15504921 Review.
An economic approach to health care.
Homik JE, Suarez-Almazor M. Homik JE, et al. Best Pract Res Clin Rheumatol. 2004 Apr;18(2):203-18. doi: 10.1016/j.berh.2004.02.001. Best Pract Res Clin Rheumatol. 2004. PMID: 15121040 Review.

Cost-effective osteoporosis treatment thresholds: the United States perspective.
Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL; National Osteoporosis Foundation Guide Committee. Tosteson AN, et al. Osteoporos Int. 2008 Apr;19(4):437-47. doi: 10.1007/s00198-007-0550-6. Epub 2008 Feb 22. Osteoporos Int. 2008. PMID: 18292976 Free PMC article.